OncoCyte Corporation recently held its Q1 2025 Earnings Call, where executives and analysts gathered to discuss the company's financial performance and strategic direction. Key attendees included Joshua Riggs, President and CEO, Andrea James, CFO, and Ekkehard Schütz, Chief Science Officer, alongside analysts from BTIG LLC, Stephens Inc., Lake Street Capital Markets LLC, Needham & Co. LLC, and B. Riley Securities, Inc. During the call, CEO Joshua Riggs highlighted the company's continued progress on its 2025 plan, stating, "We've been heads down executing on our 2025 plan." Riggs expressed confidence in OncoCyte's direction, noting increased interest from potential corporate partners in their transplant and oncology technologies as "external validation" of their strategy. CFO Andrea James shared financial highlights, reporting that pharma services revenue of $2.1 million exceeded expectations. The call emphasized OncoCyte's commitment to building a valuable business through strategic investments and partnerships. The full transcript can be accessed through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。